Cholangiocarcinoma Market to Garner US$ 429.6 Million, with a CAGR of 12.8% by 2028 | Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals,

Global Cholangiocarcinoma Market

Global Cholangiocarcinoma Market had a valuation of US$ 185.4 million in 2021 and is anticipated to grow at a CAGR of 12.8% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Rising innovative activities by drug organizations are projected to impel development of the global cholangiocarcinoma market over the conjectured timeframe. In September 2019, Merck Sharp and Dohme Corp, a drug organization, started the investigational clinical preliminary concentrate on Pembrolizumab (immunotherapy) in a blend with Gemcitabine and Cisplatin for the treatment of cholangiocarcinoma. The review is currently in Phase 3 clinical preliminaries and is anticipated to be finished by August 2023.

Request Here Free Sample Report

Effect of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has definitely impacted the conductance of clinical preliminaries. Many preliminary enrollments have been halted, and specialists are also encountering various issues related to setting up remote visits and performing lab and other review appraisals. As indicated by a review led by Medidata Solutions, Inc. (an American innovation organization that creates and showcases programming for clinical preliminaries), on April 23, 2020, 63% of review respondents revealed that pharmaceutical organizations which were leading clinical preliminaries quit selecting new patients for progressing clinical preliminaries, and 43% of the respondents have deferred their investigations. Indeed, during the COVID-19 general wellbeing crisis in March 2020, the US Food and Drug Administration (FDA) delivered rules on leading clinical preliminaries of clinical items, which were also refreshed on July 02, 2020.The rules included general contemplations to help supporters and specialists, which guarantees the security of preliminary members, and is in consistency with great clinical practice (GCP) for the length of the COVID-19 general well-being crisis.

Additionally, the expanding pervasiveness of cholangiocarcinoma is likewise expected to support development of the global cholangiocarcinoma market over the estimated timeframe. In May 2019, the frequency and death rates of cholangiocarcinoma in England were introduced at the ESMO-GI2 meeting in Barcelona, which showed that both the rate and death rates had been consistently expanding in England throughout recent years (2001–2017). In the event that this increment proceeds, by 2030, cholangiocarcinoma will not be an interesting disease.

Request Here PDF Report

Key Takeaways

The global cholangiocarcinoma market is projected to grow at a CAGR of 12.8% during the conjectured timeframe owing to increasing innovative work exercises by drug organizations, as most would consider normal to support the development of the market. In 2015, Leap Therapeutics, working as a clinical-stage biopharmaceutical organization, fostered an adapted monoclonal neutralizer, DKN-01, for the therapy of bile channel disease through its enemy of neoplastic action. The review is as of now under clinical preliminary stage I.

Among treatment types, the chemotherapy section represented the biggest piece of the pie in the global cholangiocarcinoma market in 2021. In August 2020, RenovoRx, a clinical gadget organization, declared that it had received Orphan Drug Designation by the U.S. Food and Drug Administration for RenovoCath, a novel intra-blood vessel gadget of Gemcitabine (Gemzar) for the treatment of patients with cholangiocarcinoma (CCA).

Based on circulation channel, the clinic drug store section is assessed to stand firm on a prevailing foothold in the global cholangiocarcinoma market over the estimated timeframe. Besides, the ascent in emergency clinic affirmation of patients experiencing intrahepatic cholangiocarcinoma is projected to increase the development of the medical clinic drug store portion over the estimated timeframe. As indicated by the report distributed by the National Organization for Rare Disorders in 2020, the occurrence of intrahepatic cholangiocarcinoma in the U.S. is roughly 0.7 per 100,000.

Among the districts, North America represented the biggest share of the global cholangiocarcinoma market in 2021. The U.S. is foreseen to be the most rewarding business sector for oral biologics, attributable to the expanding commonness of cholangiocarcinoma. As per the American Society of Clinical Oncology (ASCO’s) report in 2019, roughly 8,000 individuals in the U.S. were determined to have bile conduit disease in 2019.

Key companies contributing to the global cholangiocarcinoma market include Agios Pharmaceuticals, Inc., QED Therapeutics, Inc., Eisai Co., Ltd., Incyte Corporation, Delcath Systems, Inc., Imbrium Therapeutics L.P., Ability Pharmaceuticals, and RenovoRx.

Buy This Complete A Business Report

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snapshot, By Treatment Type
     • Market Snapshot, By Distribution Channel
     • Market Snapshot, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Opportunity
   • Impact Analysis
   • Pipeline Analysis
   • Regulatory Scenario
   • Market Trends
   • Key Developments
   • Epidemiology
   • PEST Analysis
   • Brand Analysis
4. Global Cholangiocarcinoma Market– Impact of Coronavirus (COVID-19) Pandemic
   • Economic Impact
   • COVID-19 Epidemiology
   • Impact on Clinical Trials and Drug Development
   • Government Initiatives
5. Global Cholangiocarcinoma Market, By Treatment Type, 2017 – 2028, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2021 and 2028 (%)
     • Y-o-Y Growth Analysis, 2017 – 2028
     • Segment Trends
   • Chemotherapy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
       • Gemcitabine
       • Cisplatin
       • Oxaliplatin
       • Capecitabine
       • 5 fluorouracil (5-FU)
   • Targeted Therapy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
       • • Pemigatinib
         • Infigratinib (Phase 3)
         • Ivosidenib (Phase 3)
   • Immunotherapy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
       • • Pembrolizumab (Phase 3)
   • Others
6. Global Cholangiocarcinoma Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2021 and 2028 (%)
     • Y-o-Y Growth Analysis, 2017 – 2028
     • Segment Trends
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Retail Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Online Pharmacies
     •  Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)

View Press Release